Dr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains.
Sponsored by AbbVie Medical Affairs + Health Impact Â
